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ABSTRACT

Tayara, Alia, University of South Alabama, B.S., University of South Alabama, May
2021. Factors Contributing to Diminished Long-Term Outcomes of Secondary Infections.
Chair of Committee: Thomas, Rich, Ph.D.
It is widely known that patients suffer diminished long-term outcomes in the years
following secondary infections, infectious diseases that occur during or after treatment of
a primary infection such as influenza or COVID-19. One common secondary infection is
pneumonia, which has become the most fatal hospital-acquired infection. The bacterium
responsible for pneumonia is known as Pseudomonas aeruginosa. The cytotoxic
supernatant in these studies was generated from a PA103 strain of Psuedomonas
aeruginosa with a type III secretion system that maintains the ability to transfer
exoenzymes ExoU and ExoT into target cells during infection. The focus of the
following studies was to investigate pathways that contribute to these diminished longterm outcomes for patients. We suggest that there is amyloid mediated disruption of βadrenergic mediated cAMP signaling. Preliminary data indicate that the cytotoxic
supernatant produced by P. aeruginosa infection of epithelial cells does not block the βadrenergic receptor well but blocks the prostaglandin receptor well. These data also
suggest that the cytotoxic supernatant produced by P. aeruginosa infection of endothelial
cells does block the β-adrenergic receptor but does not block the prostaglandin receptor
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well. Given this preliminary data, we sought to further investigate this discrepancy. We
hypothesized that the origin of the cytotoxic supernatant plays a critical role in
determining which receptor-mediated signaling pathways are inhibited in response to the
cytotoxic supernatant. Results from this study support the notion that the cytotoxic
supernatant produced by Pseudomonas aeruginosa infection of epithelial cells does not
appear to effectively block the beta-adrenergic receptor type 2 (β2AR) but may block a
subset of prostenoid (EP) receptors at the basal surface of the cell. Through these studies
we have successfully developed a protocol for screening the effects of cytotoxic
supernatant on GPCR pathways.
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CHAPTER I
INTRODUCTION

1.1 Primary and Secondary Infections
A primary infection occurs when an otherwise healthy person is infected with a
pathogen. This is often referred to as the root cause of an individual’s health issues,
while a secondary infection manifests after or during treatment of the initial infection
and is a sequela or complication of the root cause. Secondary infections are of interest
because they often lead to negative outcomes and fatal clinical complications (1).
Clinical, laboratory, and epidemiological studies have provided clear evidence that
secondary bacterial infections significantly increase the morbidity and mortality of
viral infections (2). It is important to investigate COVID-19, the flu, and hospitalacquired infections contributing to secondary infections and pneumonia.

1.1.1 COVID-19
In December 2019, several patients afflicted with an unexplained respiratory
disease emerged in Wuhan City, Hubei Province, Central China. Genome sequencing
revealed this speculated pneumonia to be an acute respiratory disease originating
from a novel coronavirus known as severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) that has since been termed Coronavirus disease 2019 (COVID-19).
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COVID-19 has since spread expansively, becoming a global pandemic, spreading to
188 countries and regions, infecting over 97.2 million people, and causing over
2,084,012 deaths as of January 21, 2021 (3).
The rapid transmission of COVID-19 has occurred via respiratory droplets and/or
human to human contact. A subset of patients experience symptoms of a
gastrointestinal infection, including nausea, vomiting, and diarrhea; however, the
chief symptoms of COVID-19 have shown to be cough, fever, fatigue, and loss of
taste or smell (4). Current findings support the notion that all populations are
susceptible to infection, although the elderly and those with preexisting conditions
including diabetes, hypertension, coronary heart disease, chronic obstructive
pulmonary disease (COPD), cerebrovascular disease, or kidney dysfunction among
others are more likely to progress into severe cases upon infection (5–8). Recent
studies indicate that in severe cases the disease affects more than just the respiratory
pathway, which serves to complicate treatment as well as diminishing future
outcomes for patients (8).
When compared to outbreaks of other recent coronaviruses including severe acute
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), in
2002 and 2012, respectively, the most recent emerging coronavirus, SARS-CoV-2,
exhibits greater contagion and a more robust pathogenicity. Studies attribute these
qualities to the high affinity that SARS-CoV-2’s spike glycoprotein has to its host
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cell-surface receptor angiotensin-converting enzyme 2 (ACE2), a receptor which is
densely distributed throughout the body and which under normal conditions helps
modulate angiotensin II’s inflammatory response, counteracting the resulting effects
of angiotensin II (9, 10).
While the clinical spectrum of SARS-CoV-2 infection appears to be wide, the
pathophysiology of COVID-19 remains unclear. The long-term morbidity and
sequelae caused by COVID-19 are yet to be clinically understood. COVID-19
patients admitted to the ICU have higher mortality (38%) than non-ICU patients (4%)
(11). Studies show that 19% of COVID-19 patients develop acute respiratory distress
syndrome (ARDS) in 1-2 days after symptom onset (8). The mortality rate of
COVID-19 patients who develop ARDS is 49% (12).
Clinical observations of COVID patients, in the short-term, have suggested that
the lungs are the most injured organs, to be followed by moderate injury in the heart,
liver, kidney, and brain. Lung biopsies of patients infected with COVID-19 manifest
in several ways: presence of pneumonia, edema, multinucleated giant cells, focal
hyperplasia of alveolar epithelial cells which has been associated with uneven
inflammatory infiltrates, and in many cases, proteinaceous exudate present with
globules (8, 13). Coinciding with later stages of infection, diffuse alveolar damage
(DAD), hemorrhage, and interstitial fibrosis have been observed (7). Additionally,
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fibrotic clots, gelatinous mucus, and disseminated intravascular coagulation (DIC) are
also present in the small airways (8, 14).
Non-coordinated responses between coagulation and fibrinolysis systems cause
systemic microthrombi in the circulatory system and resultant hemorrhage in affected
organs. Studies suggest that elevated plasminogen in patients with preexisting
conditions may be a channel that increases susceptibility to SARS-CoV-2 infection
and mortality rates (8). The leading causes of deaths are ARDS, sepsis syndrome with
multiple-organ failure (MOF), hemorrhage/coagulopathy (DIC), acute cardiac/renal
injury, and secondary bacterial infections (7, 8, 15). The rapid onset of this pandemic
has triggered a concerted, in some cases heroic, focus on short-term survival of
COVID-19 patients. Long-term outcomes of survivors have been placed on the back
burner (Appendix A).
A major consequence of disease progression in patients at later stages of infection
with COVID-19 is secondary bacterial infections. One out of every seven COVID-19
patients were found to be infected with a secondary bacterial infection, with 50% of
the fatalities during the SARS-CoV-2 epidemic caused by untreated or untreatable
secondary bacterial infections, in most cases in the lung (7).
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1.1.2 The Flu
Influenza, or flu, is a contagious respiratory infection characterized by fever,
chills, muscle aches, coughing, congestion, headache, and fatigue. Each year,
seasonal influenza afflicts millions of people causing thousands of hospitalizations
and flu-related deaths. All populations are susceptible to the infection, however, as is
the case in COVID-19 patients, those with preexisting conditions are at a higher risk
to develop severe cases (16).
In the setting of an influenza epidemic, bacterial secondary infections may have
devastating consequences, particularly in the at-risk groups mentioned earlier and the
immunocompromised and immunosuppressed. Immunosuppression is associated with
a significantly higher risk of mortality from secondary bacterial infections (17). In
2009, during the swine influenza pandemic, an increase in hospital pneumonia cases
occurred as a result of secondary bacterial pneumonia, as identified in 29–55% of the
mortalities (18–20). Up to 75% of patients infected with influenza who subsequently
acquire pneumonia are confirmed to possess bacterial co-infection, which seems to
occur frequently (21).

1.2 G Protein Coupled Receptors
G proteins are a family of proteins that act as molecular switches. G Protein
Coupled Receptors (GPCRs) are pivotal because they transduce extracellular signals
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to intracellular signals in response to a variety of stimuli; they are cell surface
receptors that ligands bind and trigger a chain of physiological events (22). In the
inactive state, G proteins bind the nucleotide GDP (guanosine diphosphate). When a
ligand binds to a GPCR, GTP (guanosine triphosphate) is exchanged for GDP, and
the G protein enters its active state. Activation of a G Protein Coupled Receptor
causes the alpha subunit of a G-protein to exchange GDP to GTP. Heterotrimeric G
proteins have three subunits: alpha, beta, and gamma, with the latter two being
referred to as the beta-gamma complex. They signal through four classes of G alpha
proteins: Gs/olf, Gi/o, G12/13, and Gq.
GPCRs have a unique structure in that they are composed of seven alpha helices,
extending in and out of the intracellular and extracellular spaces of the cell. When a
ligand binds to a GPCR, like a lock and key, the GPCR undergoes a conformational
change. The alpha subunit of the G protein is activated and exchanges GDP to GTP.
The alpha subunit then dissociates and will regulate multiple target proteins that use
ATP to relay a signal via a second messenger (22).
The -adrenergic receptor is the GPCR responsible for the classic “fight or flight”
response. There are three subtypes of this receptor: β1-ARs, β2-ARs, and β3-ARs (23).
These three subtypes of receptors facilitate many physiological responses to the
hormones epinephrine and norepinephrine. Epinephrine, or adrenaline, is the ligand
that binds to the β2-ARs (23). When the -adrenergic receptor binds to epinephrine,
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the alpha subunit on the G-protein activates and exchanges GDP with GTP,
dissociates, and targets an enzyme known as adenylate or adenylyl cyclase. Gs/olf
stimulates adenylyl cyclase. This enzyme catalyzes the cyclization of ATP to the
second messenger cAMP; increases in cAMP trigger dilation of pupils, activation of
sweat glands, and increase in heart rate that we know to be our “fight or flight”
response (22). These receptors are three of potentially thousands encoded in the
human genome (22).

1.3 Secondary Infections and Pneumonia
Pneumonia is an infection occurring in one or both of the lung region due to
inflammation of the alveoli (24). Alveoli are small air sacs that act as rapid vehicles
for gas exchange of CO2 and O2 between the lungs and blood vessels known as
capillaries. When inhaled oxygen enters the lungs and reaches the alveoli, it can then
be transferred to the blood through the capillaries and further transported throughout
the body. Similarly, when we exhale, carbon dioxide is expelled from the
bloodstream via capillaries to the alveoli and out of our bodies. It is notable that the
layers of cells that line the alveoli and capillaries are only one cell in thickness; the
barrier between air and blood is about one micron (25).
Pneumonia has become the most fatal hospital-acquired infection and, in recent
years, also one of the most common causes of death in developing countries and
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regions (24). This infection is classified by the location at which the patient acquires
the infection. The two main classifications are community and hospital acquisition
(nosocomial). Hospital-acquired pneumonia usually describes pneumonia that has
been contracted through a ventilator, which is referred to as ventilator-acquired
pneumonia (26). The severity and rate of mortality from ventilator-acquired
pneumonia is much higher than other commonly acquired hospital infections, ranging
from a 24% to 50% mortality rate after acquisition compared to the 1% to 4%
mortality rate attributed to other infections. Among patients receiving mechanical
ventilation, the leading causes for spread of bacteria are twofold (26). First, bacteria
can build up on the intubation tube of a ventilator in a biofilm fashion and thus be
transmitted from patient to patient. Second, some patients who require mechanical
ventilation suffer due to the mechanical force of the ventilator, which may injure the
lung, creating potential fluid generation and suitable conditions for the growth and
proliferation of bacteria.
Patients who survive the initial infection with pneumonia have elevated death
rates in the year following their discharge from the hospital. Secondary organ damage
displayed by patients in the following months was studied by Corrales-Medina et al.
and their findings indicated pneumonia has become a significant risk factor for death
due to a cardiovascular issue among other commonly recognized risk factors such as
diabetes, hypertension, and smoking (27). The reason for this is not yet established;
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however, it has been proposed that some sort of toxin is produced during the initial
infection with pneumonia that is not fully destroyed or removed with eradication of
the disease and therefore lends itself to correlation with a poor long-term outcome for
the patient (28).
This lends to the notion that there are lasting and real long-term outcomes after
primary and secondary infections have been removed or cleared from patients. It is
important to note the broad socioeconomic impact of this – how long and to what
extent will people be suffering from the impact of these infections? What will be the
financial burden of resulting treatments?
The focus of the following studies was to investigate pathways that contribute to
these diminished long-term outcomes for patients. We suggest that there is amyloid
mediated disruption of β-Adrenergic mediated cAMP signaling.
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CHAPTER II
HYPOTHESIS AND AIMS

Previously accumulated preliminary data indicate that the cytotoxic supernatant
produced by P. aeruginosa infection of epithelial cells does not block the betaadrenergic receptor type 2 well but blocks the prostaglandin receptor, EP2 and/or
EP4, well. These data also suggest that the cytotoxic supernatant produced by P.
aeruginosa infection of endothelial cells does block the beta-adrenergic receptor but
does not block the prostaglandin receptor well. Given these preliminary data, we
sought to further investigate this discrepancy.
We hypothesize that the origin of the cytotoxic supernatant plays a critical role in
determining which receptor-mediated signaling pathways are inhibited in response to
the cytotoxic supernatant.
The following experiments will serve to optimize conditions to determine whether
cytotoxic supernatant from epithelial cells inhibits beta-adrenergic signaling.
Specific Aim 1: Determine the effect of cytotoxic supernatant from epithelial cells on
isoproterenol-induced cAMP signals.
Specific Aim 2: Determine the effect of cytotoxic supernatant from epithelial cells on
PGE1-induced cAMP signals.
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CHAPTER III
MATERIALS AND METHODS

3.1 Cell Culture and Transfection
Rat Pulmonary Microvascular Endothelial Cells (PMVECs) were isolated from
male Sprague Dawley rats by the cell culture core of the University of South Alabama
Center for Lung Biology as previously described by King et al. (29). The purity of
PMVECs was verified by positive staining with fluorescent Griffonia simplicifolia
lectin and negative staining with fluorescent Helix pomatia lectin, which serves as a
marker for arterial endothelial cells. At this point cells were aliquoted and frozen in
liquid nitrogen. PMVECs were maintained briefly in Dulbecco's Modified Eagle's
Medium (DMEM; Life Technologies Inc., Carlsbad, CA) and supplemented with
10% (vol/vol) fetal bovine serum (Gemini), 100 U/ml penicillin, and 100 μg/ml
streptomycin, at pH 7.0. The cells were grown in 100 mm culture dishes at 37°C in a
humidified atmosphere of 95% air and 5% CO2. Confluent monolayers were passaged
using 0.25% trypsin–EDTA (Invitrogen, Carlsbad, CA). PMVECs were seeded onto
25 mm laminin-coated round glass coverslips and grown to 70–80% confluency
which took about 24 hours (30).
PMVECs were transfected with a plasmid encoding a FRET-based cAMP sensor,
pCDNA3 plasmid encoding H188 FRET-based cAMP sensor (31), using 2.5 μg
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plasmid, 3.75 μl Lipofectamine 3000, and 5 μl P3000 (Invitrogen) per well in serumfree media. The H188 FRET sensor consists of a cAMP-binding domain obtained
from exchange protein activated by cAMP (Epac) sandwiched between a donor
fluorophore, Turquoise, and an acceptor fluorophore, Venus. Transfected cells were
incubated for 48 h at 37°C. For single label controls, cultured PMVECs were
transfected with DNA encoding only either Turquoise (donor) fluorophores or Venus
(acceptor) fluorophores (30). For experiments, the cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum and grown in a 37°C incubator containing 5% CO2. From these conditions,
cytotoxic supernatants were prepared by plating 2 x 106 cells into individual 150 cm
dishes and growing them to confluence (about three to four days), using two plates
per experiment (32).

3.2 Cytotoxic Supernatant
The cytotoxic supernatant in these studies was generated from a PA103 strain of
P. aeruginosa that contains an intact type III secretion system that maintains the
ability to transfer exoenzymes ExoU and ExoT into target cells during infection.
Bacteria were streaked onto Vogel-Bonner (VB) agar plates and grown overnight at
37°C.
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Production of the supernatant involved washing one of the previously mentioned
two 150 cm dishes of PMVECs with phosphate-buffered saline, dissociating the cells
via trypsinization, and then counting them. The other dish was washed with Hank’s
Balanced Salt Solution (HBSS) and infected with the PA103 strain of P. aeruginosa
at a multiplicity of infection of 20:1. The PMVECs inoculated with bacteria were
incubated at a 37°C in a 5% CO2 incubator for 4 to 5 hours until microscopically
visible gaps were forming in the cell monolayer.
The supernatant within the dish was then collected and centrifuged for 10 minutes
to remove cellular debris. It was then poured into a syringe containing a 0.2 μm filter
at the end which allowed for passage of the supernatant through the filter, but not the
bacteria. The supernatant was then frozen at -80°C for future use (32). The following
studies included pretreatment for various time increments with 500 μl of the cytotoxic
supernatant diluted in 500 μl of HBSS.

3.3 Cyclic AMP Measurements
The method for detection of cAMP in this project will be through use of
aforementioned Förster resonance energy transfer (FRET) based cAMP probes. This
is a mechanism by which a donor fluorophore in an excited energy state is able to
transfer energy to nearby acceptor fluorophore. The likelihood that FRET will occur
is affected by the distance between these fluorophores among other properties of the
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molecules. The H188 FRET-based cAMP probe consists of a cAMP-binding domain
(cAMP-BD) obtained from an exchange protein sandwiched between a donor
fluorophore, Turquoise, and an acceptor fluorophore, Venus. When cAMP binds to
the cAMP-BD, a conformational change occurs which alters the distance between the
donor and acceptor fluorophores, altering the FRET efficiency. This change in FRET
efficiency can be measured in a variety of imaging approaches.
Cells were transfected with a cDNA3 plasmid encoding the H188 FRET-based
cAMP probe following manufacturer instructions (2.5 µg plasmid, 3.75 µl
lipofectamine 3000, and 5µl P3000). Transfected cells will be incubated for 48 hours
at 37°C.
The greatest limitation of commonly used FRET imaging systems is the low
signal-to-noise ratio (SNR). While many approaches have been developed to image
FRET, the majority are afflicted by slow speed often coupled with a low signal-tonoise ratio, when compared to a single fluorescent label. To combat this, the
Rich/Leavesley laboratory has developed and demonstrated the feasibility of a unique
high-speed excitation scan hyperspectral imaging microscope (HIFEX) which filters
the fluorescence excitation spectra rather than the traditionally filtered fluorescence
emission spectra. This method provides high transmission with low acquisition times,
which allow for real time imaging. Spectral imaging approaches were initially
developed by NASA to solve remote sensing and satellite imaging problems and has
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been previously demonstrated by the Rich/Leavesley laboratory to improve the SNR
for quantification of FRET signals (33). To acquire images on the HIFEX, a
Micromanager program will be used. This microscope will be used in future
experiments.
The studies described in this thesis involve use of an emission scanning Nikon
A1R confocal microscope. Confocal microscopy is an optical imaging technique that
aims to increase optical resolution by means of using a spatial pinhole on the detector
side to block out of focus light from arriving at the detector and in the formation of
the image. A confocal microscope typically has a photomultiplier with one bandpass
that allows for incident photons to be converted into an electrical signal (34). The
Nikon A1R confocal microscope is unique in that it has a diffraction grating which
allows spectrally dispersed light to be detected by a 32-channel array of
photomultiplier tubes.
3.4 Approach
As previously discussed, the PA103 strain of P. aeruginosa on epithelial cells was
used for these experiments due to availability and time constraints. In futures studies,
the cytotoxic supernatant from the ExoY strain will be tested on endothelial cells.
These data were compared to control experiments with no cytotoxic supernatant
pretreatment. As described previously, cells were transfected with the H188 FRET
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based cAMP probe (30). Prior to imaging, nuclei were labeled with DRAQ5. Figure 1
depicts the timeline of a typical experiment. In experiments involving pretreatment
with cytotoxic supernatant, the cells were treated with cytotoxic supernatant for ten
minutes prior to imaging which began at the 0-minute start point. At the 2-minute
mark, a baseline measurement was acquired with addition of the vehicle and
isoproterenol (a β-Adrenergic receptor agonist) or PGE1. At the 15-minute mark, all
at once, three reagents were added. 50 µM forskolin (FSK) was used as an adenylyl
cyclase activator, 10 µM rolipram was used as a PDE4 inhibitor, and 100 µM IBMX
was added as a non-specific PDE inhibitor. The presence of these reagents boosted
the amount of cAMP in the cells to ensure that the adenylate cyclase was functioning.
Five minutes later, at the 20-minute mark, the experiment was stopped.

^
^
0min. 2min.
Start Add vehicle, Iso, or PGE1
(0.1 to 1 µM)

^
15 min.
Add the combination of
50 µM FSK
10 µM rolipram,
100 µM IBMX

Figure 1. A schematic of the experimental approach.
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^
20 min
Stop

3.4.1 Statistical Analysis
To date we have insufficient data for statistical analysis. Data from at least 8
experiments per condition will be acquired to assess statistical significance. We plan
to assess average cAMP levels in cells at 1 minute and 12 minutes (see Figure 1). We
will then assess significance using a 2-way ANOVA comparing PGE1 responses to
isoproterenol responses or vehicle control to cytotoxic supernatant with a Tukey post
hoc test. p ≤ 0.05 will be considered significant.

3.5 Image Analysis
During acquisition of images, a spectral library was compiled from individual
emission spectra of each endmember, including the Turquoise and Venus
fluorophores, DRAQ5 nuclear label, and nonuniform background. The library can be
used to identify each individual in the spectra on a pixel-by-pixel basis. Two different
spectral libraries were generated from this information – one three-component library
that contains the spectra of the Turquoise, Venus, and DRAQ5, and another sixcomponent library that contains the spectra from the three-component library plus
that corresponding to each background signals. For both raw and unmixed spectral
image data, visualization occurred using NIS Elements and MATLAB software.
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The images were unmixed using the spectral libraries using custom scripts written
in the MATLAB (MathWorks) programming environment. The purpose of unmixing
is to separate and analyze the mixture of component signals in the images. Unmixed
images were smoothed using Gaussian smoothing with a [3 3 3] kernel. Gaussian
smoothing acts to reduce image noise and reduce detail for a clearer image. 4D image
data (dimensions: X, Y, Z, and wavelength) were reconstructed and resliced in the
XY, XZ, and YZ spatial planes using different custom MATLAB scripts. At this
point, a mask is applied to exclude the extracellular and nuclear regions if necessary
(30).
FRET efficiency was calculated for each resliced image and for each pixel in the
resliced image using unmixed Turquoise and Venus images. An outline of the image
analysis techniques is provided in Figure 2.
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Figure 2. Schematic representation of the steps involved in image analysis and
determination of the spatial distribution of intracellular FRET.
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CHAPTER IV
RESULTS

After image analysis, the measurement of isoproterenol-induced cAMP responses
in PMVECs as seen in Figure 3 demonstrates the widely known concept that
isoproterenol, a beta-adrenergic agonist, acts to increase the cAMP levels in the cell.
This is the expected response. Figure 4 depicts results from a PMVEC that was
pretreated with cytotoxic supernatant for 10 minutes prior to the start of the
experiment. When isoproterenol was added, the concentration of cAMP in the cells
rose accordingly. The results were similar to those in Figure 3. This indicates that in
this experiment, the cytotoxic supernatant has little to no effect on beta-adrenergic
signaling.

Figure 3. Isoproterenol-induced cAMP responses in PMVECs.
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This experiment is consistent with preliminary data indicating that the molecules
present in the cytotoxic supernatant do not block beta-adrenergic signaling
particularly well.

Figure 4. Cytotoxic supernatant from epithelial cells has little or no effect on
isoproterenol-induced signals in PMVECs.
Control experiments were performed to test the effect of the cytotoxic supernatant
alone on PMVECs, without a treatment with isoproterenol or PGE1. Data in Figure 5
indicate that the cytotoxic supernatant (and vehicle) does not significantly affect the
baseline cAMP signals in PMVECs as shown by the negligible changes in cAMP
levels as the experiment progresses. These data are consistent with the idea that the
molecules present in the cytotoxic supernatant affect signaling of specific GPCRs as
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opposed to blocking the action of the cell as a whole (e.g., by blocking adenylyl
cyclase activity or by disrupting the excitation-emission properties of the FRET-based
cAMP probe).

Figure 5. Cytotoxic supernatant (and vehicle) does not significantly affect baseline
cAMP signals in PMVECs.
Figures 6 and 7 depict the effects of the cytotoxic supernatant on prostaglandin
signaling in PMVECs.
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Figure 6. PGE1-induced cAMP responses in PMVECs.
PGE1-induced cAMP responses were tested without a pretreatment with cytotoxic
supernatant. Figure 6 depicts a typical PGE1 response; there is a slight change in
cAMP concentration but nothing significant. Overall, it remains low and localized to
certain areas in the cell. Figure 7 depicts the response of a cell pretreated with the
cytotoxic supernatant for ten minutes before the onset of the experiment and then
exposed to PGE1. As indicated by the darker blue color in the images of the basal
slice (bottom of the cell) and warmer colors in the apical and middle slices, the
cytotoxic supernatant appears to be blocking receptors only on the basal surface of
the cell. These data indicate that a component(s) within the cytotoxic supernatant
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inhibits cAMP production (or stimulates cAMP hydrolysis or extrusion) at the bottom
of the cell.

Figure 7. Cytotoxic supernatant appears to block prostaglandin signaling on the basal
surface of the cell but not the apical side.
Figure 8 is a comparison of the average cAMP concentrations in the middle slices
of cells with and without cytotoxic supernatant pretreatment and also compares
isoproterenol versus PGE1 responses in terms of cAMP concentrations. As speculated
earlier, the cytotoxic supernatant appears to have little or no effect on beta-adrenergic
signaling and the average concentration of cAMP in cells with an isoproterenolinduced response. On the right side of the figure, the PGE1 response is visible and one
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can see how the treatment with cytotoxic supernatant increases the signaling in the
middle slice of the cell.

Figure 8. A bar graph comparing average cAMP responses from a middle slice for
both isoproterenol and PGE1 responses.
In Figure 9, the average cAMP responses are compared in the basal slices of the
cell. The cytotoxic supernatant, again, seems to have little to no effect on the betaadrenergic signaling or the average cAMP level in the cell. In contrast, the PGE1
response after pretreatment with cytotoxic supernatant is greatly diminished,
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supporting the notion that the receptors on the middle slice of the cell are activated
but those on the basal slice are blocked.

Figure 9. A bar graph comparing average cAMP responses from a basal slice for both
Isoproterenol and PGE1 responses.
Ultimately, these data demonstrate that we have developed an approach to
determine the effects of cytotoxic supernatant pretreatment on GPCR signaling
pathways; however, due to a lack of repeat experiments, the effect of the cytotoxic
supernatant is not fully determined.
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CHAPTER V
DISCUSSION

To put the findings of this study into perspective, the area of our lungs coming in
contact with the air, the epithelium of the alveoli, is where the cytotoxic supernatant
originated from. Data indicate that the endothelial side, in contact with the
vasculature, may have a certain subset of receptors that are blocked as a result of
exposure to the cytotoxic supernatant produced by the epithelial cells infected with
Pseudomonas aeruginosa.
The cytotoxic supernatant produced by epithelial cells infected with Pseudomonas
aeruginosa contains components including amyloids that may block subsets of
receptors and disrupt different signaling pathways. This notion is supported by our
preliminary data and the results of this study. Our initial step in this study was to
develop an assay that can be used in a high content approach to screen for the
presence of these different molecules and their effect on cellular signaling. Moving
forward, it is important to define what these molecules are and how they work to truly
understand their effect on the body and contributions to secondary infections.
We will be using this approach in the future to screen different cytotoxic
supernatants produced from different cell types. In the studies presented here, we
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used cytotoxic supernatant produced by epithelial cells. In the future we will screen
different cytotoxic supernatants produced by several cell types in response to
different strains of Pseudomonas aeruginosa.
This overall approach is valuable because it can be used not only in the context of
the imaging of a single cell within a single well. It can be performed in a multiwell
format imaging multiple cells over a time course. This will allow us to assess the
effects of cytotoxic supernatant at different concentrations from different cell types
and from different strains of our bacteria in question, both those that are laboratory
strains and more clinically relevant strains.
It is widely known that GPCRs are associated with physiological function. Sense
of smell is related to function of GPCRs. To provide a medical application, it is
important to note that many COVID-19 patients experience loss of taste and smell,
often for extended periods of time. Amyloids may also be present in nasal secretion,
which could contribute to the disruption of taste and smell, given the understanding
supported by these studies. Another factor to understand is the importance of β2-AR
activity in the maintenance of barrier integrity of airway epithelium and endothelium.
Disruption of GPCR mediated responses may also lead to endothelial/epithelial
barrier disruption in multiple organ systems.
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A primary goal for future work would be to complete the studies initiated
described in this thesis; we estimate that 8-10 experiments would be required for each
condition. The next goal would be to examine responses at different agonist
concentrations (0.01 and 1 µM isoproterenol and PGE1). At this point, we would
utilize advanced analysis approaches (time filtering and automated thresholding) to
better assess the impact of cytotoxic supernatant on cAMP signals.
Additional studies could involve assessment of additional GPCR-mediated
signaling pathways in different cell types, for example, evaluating signaling and
barrier disruption in endothelial cells from the microvasculature of different organ
systems. Similarly, testing the effects of cytotoxic supernatant produced by different
cell types in response to a panel of Pseudomonas aeruginosa strains would provide
insight into the potential impacts of different pulmonary infections on different organ
systems. The experiential approach described in this thesis is well suited for the
preliminary screens required to assess this wide array of experiential conditions.
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CHAPTER VI
CONCLUSIONS

Our preliminary data indicate that the cytotoxic supernatant from PA103-infected
epithelial cells seems to inhibit EP2 and/or EP4 receptor-induced cAMP responses at
the basal side of the cell in PMVECs but does not inhibit B2-AR-induced cAMP
responses. These data support the notion that the source of cytotoxic supernatant is
critical in determining GPCR signaling specificity. The biological outcomes of these
studies are preliminary in nature. However, through these studies, we have
successfully developed a protocol for screening the effects of cytotoxic supernatant
on GPCR-mediated signaling pathways. The demonstration of signaling specificity
would be highly relevant in understanding disease pathways. More specifically, in
determining which GPCR pathways are actually targeted and what are the molecular
mechanisms underlying this disruption. In addition, this biochemical screen could be
used to determine which component(s) of cytotoxic supernatant trigger inhibition of
GPCR pathways.
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The following review article was submitted on June 23, 2020 to SHOCK: Injury,
Inflammation, and Sepsis: Laboratory and Clinical Approaches Journal. It is
currently under revision and will be re-submitted soon. It is titled COVID-19 and
Long-Term Outcomes: Lessons from Other Critical Care Illnesses, Possible
Mechanisms, and New Hypotheses. It is authored by Eli Arbov1, Alia Tayara, Dr.
Thomas C. Rich2,3, and Dr. Brant Wagener4. I earned co-first authorship on this paper
for my contributions in writing the manuscript.
1Morehouse
2Department
3Center
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for Lung Biology, University of South Alabama, Mobile, AL, USA
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of Critical Care Medicine and Molecular and Translational Biomedicine,

Department of Anesthesiology and Perioperative Medicine, University of Alabama at
Birmingham, AL, USA.

A.1 Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
coronavirus that is currently causing a pandemic and has been termed Coronavirus
disease 2019 (COVID-19). The elderly or those with preexisting conditions like
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diabetes, hypertension, coronary heart disease, chronic obstructive pulmonary
disease, cerebrovascular disease, or kidney dysfunction are more likely to develop
severe cases when infected. COVID-19 patients admitted to the intensive care unit
(ICU) have higher mortality than non-ICU patients.
Critical illness has consistently posed a challenge not only in terms of
mortality, but also in regard to long-term outcomes of survivors. Patients that survive
acute critical illness including, but not limited to, pulmonary and systemic insults
associated with ARDS, pneumonia, systemic inflammation, and mechanical
ventilation, patients will likely suffer from Post-ICU Syndrome (PICS), a
phenomenon of cognitive, psychiatric, and/or physical disability following treatment
in the ICU. Post-ICU morbidity and mortality continues to be a cause for concern
when considering large-scale studies showing 12-month mortality risks of 11.8% to
21%. Previous studies have demonstrated that cytotoxic amyloids are released into
human body fluids after bacterial infections; these cytotoxic amyloids lead to endorgan dysfunction in the lung and brain. We present evidence and hypothesize that
COVID-19 infection may lead to production and release of cytotoxic amyloids that
could cause acute and long-term morbidity and mortality in patients. We put forth a
call to action for all physicians and scientists to not only consider the short-term
impact of the COVID-19 pandemic, but its long-term effects that may not yet be
imagined.
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A.2 Manuscript
A.2.1 Introduction

In December 2019, several patients with unexplained pneumonia emerged in
Wuhan City, Hubei Province, Central China. Genome sequencing revealed that this
pneumonia is an acute respiratory disease originating from a novel coronavirus known
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has since been
termed Coronavirus disease 2019 (COVID-19). COVID-19 has become a global
pandemic, spreading to over 200 countries and territories, infecting more than 9 million
people and causing over 469,000 deaths to date (3).
The rapid transmission of COVID-19 occurs via respiratory droplets and/or humanto-human contact. Patients generally present with symptoms of cough, fever, fatigue,
and in a small subset of patients, gastrointestinal infection symptoms that include
diarrhea, nausea, and vomiting (4). Current findings support that all populations have
susceptibility to the disease. The elderly or those with preexisting conditions like
diabetes, hypertension, coronary heart disease, chronic obstructive pulmonary disease
(COPD), cerebrovascular disease, or kidney dysfunction are more likely to develop
severe cases when infected (5–8). Recent studies indicate that the disease affects more
than just the respiratory pathway, which serves to complicate treatment as well as
diminishing future outcomes for patients (8).

41

When compared to other recent coronaviruses such as severe acute respiratory
syndrome (SARS) and Middle East respiratory syndrome (MERS), which caused
outbreaks in 2002 and 2012, respectively, the most recent emerging coronavirus,
SARS- CoV-2, exhibits greater contagion and a more robust pathogenicity than its
predecessors. Studies attribute these qualities to the high affinity that SARS-CoV-2’s
spike glycoprotein has to its host cell-surface receptor angiotensin-converting enzyme
2 (ACE2), a receptor which is densely distributed throughout the body and which under
normal conditions, has counterbalancing protective effects (9, 10).
While the clinical spectrum of SARS-CoV-2 infection appears to be wide, the
pathophysiology of COVID-19 remains unclear (7). Additionally, being only months
removed from the earliest reports of recovered patients, the long-term morbidity and
sequalae caused by COVID-19 are yet to be clinically understood. COVID-19 patients
admitted to the ICU have higher mortality (38%) than non-ICU patients (4%) (12).
Studies show that 19% of COVID-19 patients develop acute respiratory distress
syndrome (ARDS) in 1-2 days after symptom onset (8). The mortality rate of COVID19 patients who develop ARDS is 49% (11).
Clinical observations, in the short-term, have suggested that the lungs are the most
injured organs, to be followed by moderate injury in the heart, liver, kidney, and brain.
Lung biopsies of patients infected with COVID-19 manifest in several ways: presence
of pneumonia, edema, multinucleated giant cells, focal hyperplasia of alveolar
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epithelial cells which has been associated with uneven inflammatory infiltrates, and in
many cases, proteinaceous exudate present with globules (8, 13). Coinciding with later
stages of infection, diffuse alveolar damage (DAD), hemorrhage, and interstitial
fibrosis have been observed (35). Additionally, fibrotic clots, gelatinous mucus, and
disseminated intravascular coagulation (DIC) are also present in the small airways (8,
14).
Non-coordinated responses between coagulation and fibrinolysis systems cause
systemic microthrombi in the circulatory system and resultant hemorrhage in affected
organs. Studies suggest that elevated plasminogen in patients with preexisting
conditions may be a channel that increases susceptibility to SARS-CoV-2 infection and
mortality rates (8). The leading causes of deaths are ARDS, sepsis syndrome with
multiple-organ failure (MOF), hemorrhage/coagulopathy (DIC), acute cardiac/renal
injury, and secondary bacterial infections (7, 8, 15). The rapid onset of this pandemic
has triggered a concerted, in some cases heroic, focus on short term survival of COVID19 patients. Long-term outcomes of survivors have been necessarily placed on the back
burner. Herein, we consider the long-term outcomes of COVID-19 survivors.
Specifically, we examine potential outcomes of survivors who were admitted to the
ICU as well as survivors who had less serious symptoms from the initial infection. We
also consider potential mechanisms underlying long term morbidity in COVID-19
survivors.
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A.2.2 Long Term Outcomes from Critical Illness

Illness from the COVID-19 pandemic has produced an overwhelming surge in ICU
admissions, bringing in perhaps one of the largest sequential cohorts of critically ill
patients that the United States, along with many other countries, have seen in
generations (36, 37). Global concern that critically ill patients might overwhelm
existing ICU bed availabilityalong with draconian measures employed to limit viral
transmission may be ascribed to early reports from China and Lombardy, Italy, which
had indicated a high incidence (23-32% and 16% respectively) of critical illness among
hospitalized patients positive for COVID-19 (38, 39). A Centers for Disease Control
and Prevention (CDC) morbidity and mortality report dated March 16, 2020, indicated
an ICU admission rate in the United States of between 4.9% to 11.5% among all
patients positive for COVID-19 (n=4266) (40). In the time following this CDC report,
2,287,087 new patients have tested positive throughout the U.S (3). Evolution in testing
and surveillance make these incidence rates difficult to interpret, and in fact, the exact
rate of ICU admission may never be fully known. However, it is not the exact number
of critically ill patients that is important in this context, but rather, the certainty that a
large population of patients will experience critical illness during this pandemic. In this
review, we shed light on the relationship between COVID-19 as a critical illness and
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the long-term outcomes of patients who, although recovered from initial infection, may
be subject to further complications.
Critical illness has consistently posed a challenge not only in terms of mortality,
but also in regard to long-term outcomes of survivors. Originally, the field of critical
care held its focus primarily on prolonging the life of the patient in the acute setting;
with less consideration as to the future life of the patient. It has since transitioned to
consider the challenges of survival not only from a physical, but also an emotional,
mental, and social standpoint (41). Patients who survive the acute, critical phase of
COVID-19 infection may encounter a long road of recovery. Looking at other
experiences with acute critical care, including, but not limited to, pulmonary and
systemic insults associated with ARDS, pneumonia, systemic inflammation, and
mechanical ventilation, patients will likely suffer from Post-ICU Syndrome (PICS), a
phenomenon of cognitive, psychiatric, and/or physical disability following treatment
in the ICU (42). While studies have shown that hospital survival of critically ill patients
has improved greatly in the last few decades, in large part due to advances in critical
care medicine and bundled therapy, the functional and cognitive sequelae that typifies
PICS has remained largely the same (41–43). Post-ICU morbidity and mortality
continues to be a cause for concern when considering large-scale studies showing 12month mortality risks of 11.8% to 21%, and increases in mortality risk each additional
year for at least the first 3 years (44, 45). Though mortality risk may vary considerably
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with diagnosis and other confounding factors, figures on both ends of the spectrum are
nonetheless, alarming.
In an early study from Wuhan, China, 48.6% of all patients who tested positive for
SARS-CoV-2, developed ARDS (11). Those who developed ARDS were older than
non-ARDS patients, average age being 61 years and 49 years, respectively. The subset
of patients with ARDS were more likely to have coexisting conditions, including, but
not limited to diabetes (20.8% versus 1.8%), cerebrovascular disease (11.3% versus
0%), and chronic kidney disease (15.1% versus 3.6%) (11). Those with moderate and
severe ARDS had higher mortality rates than those with less severe cases. As a result,
it has been suggested that the mortality rate increases with severity of ARDS in
COVID-19 (11).
A complication of recovery from a subset of critical illnesses including ARDS has
been cognitive decline, not only in elderly patients with pre-existing cognitive
impairments, but also the patients without previous cognitive impairments (46). Of
patients who survived ARDS, 1-year follow up indicated impaired executive function
and short-term memory. Additionally, survivors reported increased rates of anxiety and
depression, and in several cases, post-traumatic stress disorder (PTSD) (46, 47). Follow
up neurocognitive testing over time showed residual emotional and cognitive issues in
half of patients. Depression and anxiety at 1-year is coupled with impairments in
executive function, memory and learning; at 2 years post-infection there was
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performance below the 6th percentile on multiple neurocognitive tests (46, 47). Longterm observations on SARS survivors also point to cognitive declines in the years
following illness (48, 49). Given that a large subset of patients who have contracted
COVID-19 had ARDS, this is a future concern.
Cytokines are upregulated in the lungs and other organs of SARS patients, and the
systemic inflammatory response syndrome provides a possible mechanism for multiorgan failure in severe cases, that almost always involves the heart (50). The ACE2
receptor, which COVID-19 has been speculated to use as a method of transmission, is
also expressed in the heart which provides a link between coronaviruses and the
cardiovascular system. SARS-CoV has the ability to down-regulate myocardial and
pulmonary ACE2 pathways, which mediate myocardial inflammation, lung edema, and
acute respiratory failure (50, 51). In the aforementioned study, of 191 patients, 58
developed hypertension (30%), 15 developed coronary artery disease (8%), 44
experienced heart failure (23%), and 33 experienced acute cardiac injury (17%) (7).
Sepsis is a debilitating syndrome that arises when the body mounts an immune
response that becomes dysregulated and causes end-organ dysfunction (52). ICU
contraction of sepsis generally has a 17% mortality rate. Two and three-year mortality
rates for those infected among survivors of “severe” sepsis are 45% and 71%
respectively (53). In 35% of cases, sepsis “survivors” are discharged to long-term acute
care and skilled nursing facilities (53). Over time, patients experience a sustained
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decline in physical activity, exercise capacity, and muscle strength. Almost all patients
are at an increased risk of cardiovascular events and have long-term neurocognitive
decline with increased risk of developing dementia. In a study of 191 patients infected
with COVID-19, 112 patients had sepsis (59%) and of those, 54 were non-survivors,
100% being septic (7). Sepsis has also been associated with the highest incidence of
neurological implications (54).
Critical illness that culminates during the course of infection of COVID-19—
ARDS, pneumonia, septic shock, MOF, opportunistic secondary infections, etc.—bear
a striking semblance to the conditions that admit non-COVID-19 patients to the ICU
(55). Knowing the historical outcomes of critically ill patients, it is important to
consider that even when this current pandemic does end, the toll it will leave on its
patients—the cognitive impairments and long-term health threats—will continue to be
seen for many years to come. Therefore, analyzing the causative mechanisms for the
potential long-term risks that we will see following COVID-19 remains an important
concern. Based on current literature, we present possible mechanism(s) by which
COVID-19 infection may lead to long term morbidity.

A.2.3 Potential Mechanisms of Long-Term Morbidity
We suggest SARS-CoV-2, through infection of the alveolar epithelium and damage
of endothelium in infected tissue, may have the ability to elicit the production and
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release of amyloid-like substances, which exhibit self-propagating features. Such a
substance could target tissues throughout the body and potentiate various types of endorgan failures at sites distant from the original site of infection (56). This may help
explain the elevated levels of mortality following recovery from certain infections.
The idea that infection, whether by virus, bacteria, or fungi, can generate cytotoxic
molecules with prion-like activity is not entirely new. Alois Alzheimer, the man
credited with identifying the disease that is perhaps most popularly linked to βAmyloids (Aβ), also considered a role for infection when considering its pathogenesis
(57). This construct for amyloid pathology has evolved into what is known as the
“infection hypothesis,” a construct that has traditionally received little attention. Recent
findings however, such as those that identify Aβ as a class of antimicrobial peptides
(AMP) acting against viruses, bacteria, and fungi, whose concentrations increase
during microbial infection, have revitalized interest in this age-old theory (57, 58).
Empirical backing for the infection hypothesis of amyloidosis leading to end-organ
dysfunction was again raised when a pre-clinical study demonstrated that neurological
impairment and end-organ dysfunction in survivors of critical illnesses might be related
to Aβ and tau oligomer formation, particularly in patients with nosocomial pneumonia
(28). Pneumonia is a serious pulmonary infection that can result from a variety of
microbes such as viruses, bacteria, or fungi. In the U.S. alone, pneumonia results in
upwards of 50,000 deaths each year (59). It is well established that patients who recover
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from pneumonia subsequently have elevated rates of mortality following hospital
discharge, often attributed to secondary organ damage (28, 60, 61). Additionally,
growing evidence suggests that survivors of critical illness such as sepsis and
pneumonia, exhibit long-term neurological sequelae and declines in cognitive function
(62). While these clinical trends appear to be clear, their causative mechanisms are still
unknown.
Attempting to elucidate this phenomenon, Balczon et al. utilized Pseudomonas
aeruginosa, a Gram-negative opportunistic pathogen and common culprit of
nosocomial and ventilator-associated pneumonia, as a model system of infection in
isolated pulmonary microvascular endothelial cells (28, 63). Their work revealed that
a common infectious bacterium is a trigger for the formation of a transmissible
cytotoxic amyloid agent—namely, that acute P. aeruginosa infection elicits the
production of cytotoxic tau and oligomeric β-amyloid (Aβ) species from pulmonary
endothelium (28). These cytotoxic products are released into the blood of patients and
become detectable in the bronchoalveolar lavage fluid (BALF), plasma, and
cerebrospinal fluid (CSF) of patients, revealing how both peripheral structures and the
brain can be affected (28, 64, 65).
Balczon et al. described how supernatant from pulmonary microvascular
endothelial cells (PMVEC) infected by P. aeruginosa could initiate cytotoxicity and
cell death in naïve PMCESs and neurons (28). Furthermore, after incubating unexposed
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cells with the supernatant from previously infected PMVECs, naïve cells are shown to
contain transmissible and self-replicating τ and Aβ oligomers (28, 66). The results
demonstrate that P. aeruginosa infection of PMVECs elicits the production of
cytotoxic agents which have the capacity to damage naïve and unexposed cells of
varying tissue types in the absence of the originating infectious pathogen (28). Such a
finding may help explain how patients who recover from infection subsequently
succumb to secondary organ failure, even after rigorous antibiotic treatment (28).
In a separate study, Lin et al. demonstrated how infection-induced amyloids
impaired memory through neuronal harm and disruptions of synaptic plasticity, further
establishing a potential mechanism for the neurologic decline seen in patients who
suffer from critical illness (66). These authors reported that supernatant prepared from
pulmonary endothelium infected in vitro with Klebsiella pneumoniae or
Staphylococcus aureus (isolated from BALF of intubated patients with nosocomial
pneumonia) exhibits neurotoxicity (66). Furthermore, in ex vivo electrophysiology
assays, rodent hippocampal slices bathed in cerebrospinal fluid (CSF) of patients with
nosocomial pneumonia demonstrated severely impaired or abolished long-term
potentiation (LTP) compared to CSF from uninfected patients (65, 66).
It is important to consider that the phenomenon formerly described—pulmonary
endothelial liberation of amyloid cytotoxins which exhibit features of self-replication
and transmission among cells—is at present shown only with P. aeruginosa, Klebsiella
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pneumoniae, and Staphylococcus aureus, as experiments with other pathogenic
sources, to our knowledge, have not been performed in this context. It remains possible
that during infection other bacteria elicit similar responses to those elicited by P.
aeruginosa. Likewise, through unique mechanisms of their own, other microbes such
as viruses or fungi may display similar effects.
The aforementioned studies have far-reaching implications. Considering that the
disease prognosis in COVID-19 has largely been influenced by multiple-organ
involvement, attention must be paid to these long-term implications in the face of this
pandemic (67). Considering the parallels of septic shock, pneumonia, dementia, and
multiple organ failure in COVID-19 and non-COVID-19 critical illness, further
investigation should be made.
The infection hypothesis is also supported by reports suggesting a viral link to
amyloid-related pathologies. Alzheimer’s Disease (AD) offers an interesting and
relevant perspective as we consider the theory that viral infections, such as COVID-19,
could lead to long-term sequelae through the production of cytotoxic amyloid species,
because AD, which is characteristically an amyloid syndrome, has long been suspected
of having a viral etiology (57).
In 1982, MJ Ball first suggested that a virus, herpes simplex virus type 1 (HSV-1),
might be involved in the pathogenesis of AD, after observing that brain regions
damaged during herpes encephalitis (limbic system, frontal and temporal cortices) are
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the same regions that are compromised in AD (68). In the decades since, several studies
have reinforced these observations while providing considerable support to suggest
viral involvement in AD pathogenesis and associated amyloidopathies (69). In an
examination of human AD brains, researchers found a striking localization of HSV-1
DNA within amyloid plaques, with 90% of plaques containing viral DNA and 72% of
viral DNA within the brain associated with plaques (70). In a separate study, infection
of cultured neuronal and glial cells with HSV-1 resulted in dramatic increases in
intracellular Aβ 1-40 and 1-42 and parallel decreases in amyloid precursor protein
(APP), resulting from the increasing levels of beta-site APP-cleaving enzyme (BACE1), a component of gamma-secretase, in HSV-1 infected cells (71). Several studies have
demonstrated that HSV-1 can induce amyloidogenic APP cleavage in cultured cells
(72, 73).
In carriers of the apolipoprotein E allele 4 (ApoE ε4), a well-proven genetic risk
factor for late-onset AD, it has been shown that brain infection with HSV-1 immensely
elevates the incidence of AD (74). Individuals who do not express the ApoE4 allele on
the other hand, when infected with HSV-1 do not experience any greater incidence of
AD (74). Observations that HSV-1 is also present in the brains of patients without AD
reveals that HSV-1 alone is not an independent cause of AD. Such findings suggest
that rather than a cause for AD, HSV-1 acts as a cofactor for the disease along with
ApoE4, supporting the belief that pathogens interact with genetics and environmental

53

factors in order to initiate the formation and accumulation of Aβ or the
hyperphosphorylation of tau (57, 75). Significant associations have also been made
between AD and a variety of different pathogens, including Cytomegalovirus and other
Herpesviridae, Chlamydophila pneumoniae, spirochetes and Helicobacter pylori (76).
Although it has not been proven that viruses alone cause amyloid-related diseases
such as AD, it has been shown that an association more than likely does exist.
Incredibly, the work of Soscia, et al., indicates that Aβ is an antimicrobial protein
(AMP) active against numerous bacteria and fungi (77). Additionally, Bourgade, et al.
helps reveal antiviral activity associated with Aβ (78). Bourgade et al. shows that Aβ
1-40,1-42 inhibits HSV-1 replication when exposed to cell lines (neuronal, epithelial,
and fibroblast) either prior to or concomitantly with viral challenge of HSV-1 (78).
Also, it was shown that Aβ does not inhibit viral replication of non-enveloped human
adenoviruses (78). Viral interference was recognized by the scientists as a consequence
of a sequence homology between Aβ and a proximal transmembrane region of
glycoprotein B of HSV-1 (78). Indeed, without functionality of a glycoprotein essential
for host-cell interaction, Aβ represents a novel class of antimicrobial peptides capable
of protecting against enveloped viral infections (78). Studies also show that Aβ
peptides display antiviral activities against enveloped Influenza A virus (79).
Interestingly, SARS-CoV-2 is also an enveloped virus that depends exclusively on its
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transmembrane glycoprotein (spike glycoprotein S) for receptor-binding and
subsequent fusion functions.

A.2.4 New Directions for the Study of Patient Outcomes
In the face of our current pandemic, our lessons from SARS and MERS have proved
instrumental in our early stages of understanding and response and will continue as a
baseline guide for what we can expect, at the very least, after this pandemic ends. Much
of what we know about the course of COVID-19 continues to be learned, though,
largely through our clinical observations. Thus, while coronaviruses may be
phylogenetically related, much in the way they behave may not be. Epidemiological
characteristics between SARS-CoV-2, SARS-CoV, and MERS-CoV, show that SARSCoV-2 presents a higher asymptomatic viral load, a longer period of infectivity, a
longer median incubation period (SARS-CoV-2: 6.4d [0-24], SARS-CoV: 4.6d [3.85.8], MERS-CoV: 5.2d [1.9-14.7]), and a shorter serial interval (SARS-CoV-2: 2.67.5d, SARS-CoV: 8.4d, MERS-CoV: 12.6d) (80). With a mean serial interval for
COVID-19 considerably shorter than that of SARS or MERS, the exponential growth
of this pandemic along with our struggles to control it, become obvious. The 8,439
confirmed cases of SARS and the 2,519 confirmed cases of MERS dwarf in comparison
to the current global estimations of 9,006,757 confirmed cases of COVID-19, a number
that only continues to grow (3, 81, 82). This sheer volume of cases, while leading us to
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the largest surviving cohort of any previous coronavirus outbreak in recorded history,
will also allow us to learn more about the sequalae experienced by COVID-19
survivors.
We do not know how people will clear infections. If COVID-19 ends up being an
acute infection, like SARS and MERS, most recovered patients should develop at least
a short-term immunity. Alternatively, it is also possible that the virus may persist as a
latent infection—like varicella-zoster, herpes simplex, Epstein-Barr, Cytomegalovirus,
and many others—persisting latent in the body, only to re-emerge sporadically as
shingles does, or develop into a chronic infection, like hepatitis B, living within the
body for a sustained period of time, causing long-term damage. This would not be the
first time after a global outbreak where we find unexpected sequelae; for example,
sequelae revealed in the aftermath of the Ebola virus disease (EVD) outbreak of 20132016. In EVD survivors, the persistence of a variety of clinical symptoms during
convalescence—colloquially termed ‘post-Ebola virus disease syndrome (PEVDS)’—
included ocular disease including most notably uveitis, arthritis, hearing loss,
abdominal pain, neuropsychiatric disorders, as well as viral persistence in immuneprivileged organs, among others (83). Similar to the sequelae seen in SARS survivors,
the exact pathogenesis of the PEVDS remains unclear. We suggest a series of potential
mechanism(s) by which amyloids could be released during COVID-19 infection or its
related sequelae (Figure 1) and lead to end-organ dysfunction and long-term morbidity.
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First, it is possible that amyloids are antimicrobial, and their function becomes
dysregulated consistent with the pathology of sepsis. In this case, the amyloids may
have the same amino acid sequence, but change their phenotype in various posttranslational modifications. Second, it is possible that viral infection of alveolar
epithelial cells (and other cell types thereafter) lead to direct release of cytotoxic
amyloids. This hypothesis is supported by the fact that viral infections have been
associated with amyloids release (70, 72, 75, 78) and bacterial infections produce
cytotoxic amyloids (28). Third, COVID-19 infection led to secondary bacterial
pneumonia in a high percentage of patients that died in an early study out of Wuhan,
China (7). It is already well known that many diseased states result in an increased
susceptibility to secondary infections, an in fact, secondary infections with bacterial,
viral, and other pathogens are a well-described phenomenon in influenza, SARS, and
MERS among other respiratory illnesses, and while data regarding co-infections in
COVID-19 pneumonia are still emerging, a number of studies describe such
occurrences (12, 84). It is possible that the secondary bacterial infection leads to release
of cytotoxic amyloids and only patients with these infections are subject to amyloidrelated effects.
Measuring such outcomes (presence of amyloids and cytotoxicity) can be done with
relative ease; these studies are currently ongoing. Importantly, the measurements (via
serum) should take place at varying times during a patient’s hospital stay and after
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important events. For example, it would be important to know the levels of cytotoxic
amyloids at admission, if there were admission to the ICU, diagnosis of bacterial
pneumonia and during convalescence from the infection(s). Furthermore, as long-term
outcomes are important within this context, we suggest long term monitoring of patient
function (e.g., pulmonary, cardiac, and neurologic function) at weeks, months and, if
possible, years after discharge.

A.2.5 Conclusions
Our review focuses on the long-term outcomes from COVID-19 infection and its
potential mechanism(s). While we focus specifically on amyloids and their potential
toxicity, we acknowledge that this may be only one of many contributing factors to the
overall pathophysiology. Other potential factors include, but are not limited to,
cytokine release, adaptive immune responses, nutrition, sedation, race, sex, age and
availability of resources during recovery. Most work that has been done regarding
COVID-19 has focused on acute infection and therapies to control maximize patient
survival, and rightly so. However, as patients recover from the infection, whether they
have been hospitalized, in the ICU or outpatient, they may experience long-term
morbidity. Even in patients who are in the “mildly symptomatic” category, according
to a recent study out of the Netherlands, turn out to be substantially burdened by the
lingering effects of their illness months after their recovery, with many reporting
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symptoms as shortness of breath, extreme fatigue, intermittent fevers, cough,
concentration issues, headaches, or heart palpitations (85). Clearly then, this is an
opportunity for we as physicians and scientists to establish long-term observation of
the disease via testing (e.g., pulmonary function tests, transthoracic echocardiography,
blood tests) and understand mechanism(s) of long-term morbidity in survivors. A
complimentary example of sort and long-term morbidity was observed in survivors and
first-responders of the 9/11 incidents (86). Victims and workers exposed to the dust
and airborne toxicants from the initial incident and the subsequent clean-up have
significant long-term health consequences that we continue to deal with as a nation to
this day, from obstructive airway disease, chronic rhinosinusitis, gastroesophageal
reflux disease, and remain at higher risk for cancers such as multiple myeloma (86).
We therefore advocate for a “Call to Action” of our colleagues within the sepsis
community to find ways to address these long-term outcomes. It is entirely possible
that may be fighting the effects of COVID-19 for multiple years to come and we should
look towards this fight sooner rather than later.
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APPENDIX B

I contributed to the following proceedings paper by performing imaging with the
Excitation Scanning Hyperspectral Imaging microscope (HIFEX). It is titled
Comparison of Spectral FRET Microscopy Approaches for Single Cell Analysis. It is
authored by Joshua Deal1,2,3, Naga Annamdevula2,3, Donald John Pleshinger2,3, John
Robert Griswold1, Aliyah Odom1, Alia Tayara, Malvika Lall5, Craig Browning1,4,
Marina Parker1,4, Thomas C. Rich2,3, Silas J. Leavesley1,2,3.
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B.1 Abstract
Förster resonance energy transfer (FRET) is a valuable tool for measuring
molecular distances and the effects of biological processes such as cyclic nucleotide
messenger signaling and protein localization. Most FRET techniques require two
fluorescent proteins with overlapping excitation/emission spectral pairing to
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maximize detection sensitivity and FRET efficiency. FRET microscopy often utilizes
differing peak intensities of the selected fluorophores measured through different
optical filter sets to estimate the FRET index or efficiency. Microscopy platforms
used to make these measurements include wide-field, laser scanning confocal, and
fluorescence lifetime imaging. Each platform has associated advantages and
disadvantages, such as speed, sensitivity, specificity, out-of-focus fluorescence, and
Zresolution.
In this study, we report comparisons among multiple microscopy and spectral
filtering platforms such as standard 2-filter FRET, emission-scanning hyperspectral
imaging, and excitation-scanning hyperspectral imaging. Samples of human
embryonic kidney (HEK293) cells were grown on laminin-coated 28 mm round
gridded glass coverslips (10816, Ibidi, Fitchburg, Wisconsin) and transfected with
adenovirus encoding a cAMP-sensing FRET probe composed of a FRET donor
(Turquoise) and acceptor (Venus). Additionally, 3 FRET “controls” with fixed linker
lengths between Turquoise and Venus proteins were used for inter-platform
validation. Grid locations were logged, recorded with light micrographs, and used to
ensure that whole-cell FRET was compared on a cell-by-cell basis among the
different microscopy platforms. FRET efficiencies were also calculated and compared
for each method. Preliminary results indicate that hyperspectral methods increase the
signal-to-noise ratio compared to a standard 2-filter approach.
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B.2 Manuscript
B.2.1 Introduction

Förster resonance energy transfer (FRET) is a distance-dependent process by
which energy is nonradiatively transferred from an excited fluorescent molecule,
called the donor, to another fluorescent molecule, called the acceptor.1 Several criteria
must be met in order for this energy transfer to take place, such as a minimum
distance between the fluorescent molecules (1-10 nm) and an overlap between the
emission spectrum of the donor molecule and the excitation spectrum of the acceptor
molecule.2–4 As the efficiency of this energy transfer is directly related to the distance
between the donor-acceptor pair, FRET is often used as a molecular ruler to
determine whether two molecules interact.
Many FRET microscopy techniques have been developed to take advantage of
this phenomenon, each with their advantages and disadvantages. The simplest
technique utilizes widefield microscopy and specially chosen filter sets. For example,
one may make use of a well-established donor-acceptor pair and associated
fluorescence filters to excite the donor molecule and compare emitted light captured
using the donor’s emission filter compared to the acceptor’s emission filter.5
However, as with most widefield microscopy applications, out-of-focus light limits
signal resolution and therefore data interpretation. Many labs, including ours, have
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taken advantage of confocal microscopy’s ability to select only infocus light and
segment the z-dimension, resulting in highly accurate FRET measurements across
entire cells.6 Furthermore, we have used the confocal approach in conjunction with
spectral imaging technologies originally created by NASA7 to isolate the individual
fluorescent molecules by their spectral signatures.6 Doing so has allowed delineation
of the fluorophores in the donor-acceptor pair from other labels and even
autofluorescence, resulting in highly accurate FRET measurements. However, the
major drawback of this technique is the time require to complete such a scan. A fivedimensional scan (x, y, z, λ, t) can take several minutes to acquire all necessary
information to facilitate accurate FRET measurements.
We have recently developed a technique that greatly reduces the time needed
for spectral scans. Our technique, called hyperspectral imaging fluorescence
excitation-scanning (HIFEX) microscopy, scans the excitation spectrum of
fluorescent molecules by varying excitation light from a Xe arc lamp in narrow bands
using an array of thin-film tunable filters in a tunable filter assembly and collects all
emitted light of wavelengths longer than our dichroic beam splitter.8 This method
allows detection of appreciably more emitted light while simultaneously reducing the
acquisition time required for data collection and has even shown a higher signal-tonoise ratio of unmixed spectral data when compared to similar emission scanning
systems.9,10 Initial studies utilizing this system’s approach to investigate FRET signals
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appear promising. Here, we present data comparing the spectral emission scanning
confocal approach with the HIFEX approach on samples fixed on gridded coverslips
which allowed us to compare the same set of cells across multiple microscopy
platforms.

B.2.2 Methods
B.2.2.1 Sample Preparation
Human embryonic kidney (HEK293) cells were cultured as described
previously.6,11,12 Cells were grown to confluency on 28 mm round gridded glass
coverslips (10816, Ibidi) and transfected with adenovirus encoding a cAMPsensing
FRET probe composed of a FRET donor (Turquoise) and acceptor (Venus). After
confluency and transfection, the gridded coverslips were mounted on slides using
ProLong Diamond Antifade Mountant (P36965, Invitrogen).
B.2.2.2 Image Acquisition
Imaging was performed on two microscopy platforms: spectral FRET imaging
using a Nikon A1R confocal microscope6 and a custom hyperspectral imaging
fluorescence excitation-scanning (HIFEX) widefield microscope.8 All images were
acquired with respect to grid locations of the coverslips, which were logged and
recorded with light micrographs to allow data acquisition from the same cell clusters
on each microscopy platform.
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The Nikon A1R confocal microscope collected image stacks at excitation
wavelengths of 405 nm (8% laser intensity) and 562 nm (6% laser intensity) and
emission wavelengths from 412 nm to 698 nm in 6 nm increments. Spectral images
were collected with a pinhole diameter of 2 airy disk units (AU). For this application,
a 60X water immersion objective (Plan Apo VC 60X DIC N2 WI NA-1.3; Nikon
Instruments) and 32 channel photomultiplier tube (PMT) spectral detector were used.
The HIFEX widefield microscope utilized a Xe arc lamp and thin-film tunable
filter assembly for spectral excitation over the range of 340 nm to 485 nm and
emission detection from 495 nm to 1000 nm. Filter cubes were used to separate
excitation and emission light at 458 nm and 495 nm for donor and acceptor signals.
These filter cubes consisted of dichroic beamsplitters (FF458-Di02 and FF495-Di03,
Semrock, Inc.) and long-pass emission filters (BLP01-458R and FF01 496/LP-25,
Semrock Inc.) Similar to the confocal platform, a 60X water immersion objective
(Plan Apo VC 60X/1.2 WI ∞.0.15-0.18 WD 0.27, Nikon Instruments) was used.
Emitted light was captured with an sCMOS camera (Prime 95B, Photometrics).
B.2.2.3 Image Processing and Analysis
Following image data collection, images were stitched using Fiji’s
Grid/Collection Stitching plugin.13 Stitched images were opened in Fiji to ensure
visual accuracy. The stitched HIFEX spectral image cube was then separated into
respective spectral bands for unmixing, as described previously.14 Confocal spectral
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image cubes were also unmixed, as described previously.6 All calculations were
performed using custom MATLAB scripts and previously acquired control library
data for each fluorescent molecule. Unmixed HIFEX and confocal data were used to
estimate FRET efficiencies and/or indices of manually selected cells as previously
described.6,11,15–17

B.2.3 Results and Discussion
Upon utilizing two microscopy platforms, confocal microscopy and
hyperspectral imaging fluorescence excitation scanning (HIFEX) microscopy, the
initial result yielded similar fields of view. This allowed confirmation that grid
locations of each scan were well documented and that subsequent stitched images
from each microscopy platform would be visually comparable. As Figure 1 shows,
the same cell clusters from the fixed slide are readily identifiable between the two
microscopy platforms. As expected, the confocal image is less hazy than the HIFEX
image, as the HIFEX image was captured with widefield microscopy. It is worth
noting that since factors such as detector type and scanning method vary between the
two systems, the HIFEX and confocal images are slightly different sizes, both in
terms of pixel count and viewing area.
Regions of interest were chosen such that cells appearing to be abundantly
bright were ignored. Extremely bright cells are often compromised in viability,
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increasingly the likelihood that any conclusions drawn from these cells would
generate misleading data. Figure 2 shows the 5 cells selected for this initial study.
The ovals in Figure 2 serve only to draw attention to the individual cells used to
obtain data, while Figure 3 demonstrates two important points. First, that a high zoom
is necessary to outline the individual features of each cell to ensure background, stray,
out-of-focus, or otherwise inappropriate light is excluded from the region of interest.
Second, that since the HIFEX data was acquired with widefield microscopy, regions
of interest needed to be drawn with respect to the confocal microscopy image in order
to maintain a direct comparison.
As FRET approximation via fluorescence excitation-scanning is a newer
concept, Figure 4 has been included to demonstrate the four scans necessary for
FRET calculations. Figure 4 shows the scans acquired with the 458 nm dichroic filter
cube and the 495 nm dichroic filter cube, unmixed into their respective fluorescence
signals. For the sake of direct comparison, each image has had the maximum
displayed value set to 30,000 (of the total available 65,535). As expected, unmixing
the data collected using the 458 nm dichroic filter cube resulted in mostly donor
signal, as the acceptor is difficult to excite with such short wavelengths. (The
excitation and emission spectra of the donor and acceptor are shown in Figure 5. 18–
20)

However, upon excitation of wavelengths longer than 475 nm, the acceptor is

more easily excitable than the donor. Thus, it is unsurprising that the unmixed data
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from the 495 nm dichroic filter cube shows the acceptor as the most intense of all of
the fields of view, as the acceptor molecules are not only directly excited by the light
source, but are also potentially excited by any nearby donor molecules via FRET.
Comparison of the overall fluorescence images, summed intensity images, and
the unmixed intensity images indicated that the two datasets were a suitable platform
to compare FRET measurements among systems. Interestingly, while the FRET
measurements made with the confocal data adhere to the traditional FRET efficiency
values between 0 and 1, the index created via analysis of the HIFEX images reported
numbers between -1 and 1. Shown in Table 1, the five cells selected here had FRET
efficiency values between 0.17 and 0.24 when the confocal images were analyzed, yet
the HIFEX data yielded FRET indices of either about -0.06 or -0.20. Furthermore,
there appear to be two relationships between the confocal data and the HIFEX data.
To elucidate any possible connection between the two values, the HIFX FRET index
values were divided by the confocal FRET efficiencies. Curiously, the ratio was
either near -0.28 or -0.96.
There are a few potential reasons for the discrepancies between the FRET
indices/efficiencies reported by the two methods shown here. First and most
obviously, confocal microscopy allows for sectioning of the focal plane such that a
single cell layer may be isolated for study. The cells used for this study (HEK293) are
notorious for growing in clusters that often overlap. Some differences in FRET
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measurements may simply be inclusion of cells above or below the focal plane in the
HIFEX image that were absent from the confocal image. Second, the FRET
measurements reported from the confocal microscopy data are a result of rigorous and
proven methods that account for factors such as the quantum yield of the individual
fluorescent molecules in the FRET pair. The method used here to calculate FRET
indices from the HIFEX data made several assumptions, including those of quantum
yield of the fluorescent molecules, concentration of the probe in the sample, and the
efficiencies of the measurement system.17 Third, the images used for unmixing the
data acquired by the HIFEX microscopy system were not corrected for background
light or wavelength-dependent illumination intensity.

Table 1. FRET indices and efficiencies for two methods of calculating FRET. The
second column reports the FRET indices per cell when estimated using the HIFEX
method. The third column reports the FRET efficiencies per cell when calculated
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using the confocal method. The last column is a ratio of the HIFEX FRET index to
the confocal FRET efficiency.

B.2.4 Conclusions and Future Work
FRET measurements among microscopy platforms is a relatively
uninvestigated topic. It should be quite important to verify that FRET measurements
made on one system agree with those made on another. Otherwise, conclusions drawn
from one FRET experiment may directly disagree with that of similar experiment
when, in fact, the only difference may be a scaling term that would adjust the values
so that conclusions agree. Here, we have shown preliminary results that begin to
approach that verification. However, it is clear that there are inconsistencies
somewhere in our HIFEX results, as the values among indices do not have a clear
correlation with those reported using confocal microscopy. Furthermore, manually
selected regions in both images to ensure comparable cell geometries. It is possible
that some or all of the selected cells were outliers.
In the future, we will reevaluate the calculation of our FRET index from
HIFEX datasets. Furthermore, we will collect data using multiple types of FRET
probes, such as those with varied lengths between the donor and acceptor proteins
which should allow us to more accurately relate FRET efficiency values. Finally, we
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plan to include other types of microscopy platforms, such as fluorescence lifetime
imaging (FLIM) to better assess the variation among platforms.
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B.3 Figures

Figure 1. Stitched HIFEX and confocal fluorescence images. (Left) The HIFEX
image shows all fluorescing molecules excited by the excitation-scanning system.
(Right) The confocal image shows all fluorescing molecules excited by the lasers on
the confocal system. Each image is a sum of the intensity through the spectral data
cube.
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Figure 2. Regions of interest selected for FRET estimation comparison among
microscopy platform. (Left) The stitched confocal fluorescence image from Figure 1,
provided as a reference for the selected cells. (Right) The same confocal fluorescence
image with five cells highlighted for FRET estimation. The selected regions are
color-coded for ease of identification. 1. Red. 2. Blue. 3. Green. 4. Magenta. 5.
Yellow.
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Figure 3. Zoomed images of the fifth selected region from Figure 2. (Left) A zoomed
image of “cell 5” from the HIFEX image. (Center) A zoomed image of “cell 5” from
the confocal image. (Right) An image of the same “cell 5” captured using the HIFEX
approach with a region of interest drawn to coincide with the cell shown in the
confocal image. As the HIFEX method utilizes widefield microscopy, its images
potentially include light from out-of-focus cells. By selecting only the regions which
also appear in the confocal image, a more appropriate comparison may be made
between FRET estimations.
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Figure 4. Linearly unmixed excitation-scanning (HIFEX) spectral images
corresponding to the donor and acceptor molecules with respect to the dichroic filter
cube used to obtain the images. All pixel intensities were scaled such that the
maximum displayed value was 30,000 (of the total available 65,535) to provide a
visual representation of the differences in fluorescence intensities among the unmixed
images. (Top Left) The unmixed donor image acquired using the 458 nm dichroic
filter cube. (Bottom Left) The unmixed acceptor image acquired using the 458 nm
dichroic filter cube. (Top Right) The unmixed donor image acquired using the 495
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nm dichroic filter cube. (Bottom Right) The unmixed acceptor image acquired using
the 495 nm dichroic filter cube. The unmixed acceptor image acquired using the 458
dichroic filter cube is the dimmest image, as the acceptor is difficult to excite with
wavelengths shorter than 475 nm. However, the unmixed acceptor acquired using the
495 dichroic filter cube is the brightest image, as the acceptor can potentially be
excited directly or through FRET.

Figure 5. The excitation and emission spectra of the donor and acceptor FRET
molecules. Excitation spectra are shown as dashed lines. Emission spectra are
represented by solid lines. The donor spectra are shown as blue and the acceptor
spectra are shown as orange. Of particular interest for the HIFEX method are the
excitation spectra at the 450 nm and 495 nm regions, as the intensities plotted
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demonstrate the difficulty of exciting the acceptor when using the 458 nm dichroic
filter cube and the change in preferential molecule excitation around 475 nm.
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